YIL142C-A Antibody

What are the common modifications introduced into antibodies to improve their half-life, and how do they affect functionality?

Several defined mutations can be introduced into the crystallizable fragment (Fc) domains of therapeutic monoclonal antibodies to extend half-life and enhance effector functions. The most researched modifications include:

• YTE mutation (M252Y/S254T/T256E): Located at the CH2-CH3 interface in the Fc domain, these mutations increase binding affinity to the neonatal FcR (FcRn) at pH 6.0, improving recycling of administered IgG1 antibodies and extending plasma retention .

• LS mutation (M428L/N434S): Similar to YTE, these modifications target the Fc domain to enhance FcRn binding and extend circulation time .

When designing experimental approaches involving modified antibodies, researchers should consider incorporating pharmacokinetic assessments including Mean Retention Time (MRT), Maximum concentration (Cmax), half-life (T1/2), and area under curve (AUC) measurements to fully characterize the impact of modifications .

What databases are available for researchers studying therapeutic antibodies?

The Antibody Society's YAbS (Antibody Therapeutics Database) is a comprehensive resource for researchers tracking therapeutic antibody development. Key features include:

• Coverage of over 2,900 commercially sponsored investigational antibody candidates that have entered clinical study since 2000

• Detailed information on over 450 late-stage clinical pipeline molecules and approved antibody therapeutics

• Open access through https://db.antibodysociety.org

• Data on molecular format, targeted antigen, development status, indications studied, and clinical timelines

• Geographical information on company sponsors

The database supports in-depth industry trends analysis and can be used to identify innovative developments and assess success rates. YAbS data can be used to:

• Track company portfolios and upcoming events in real-time

• Analyze trends in innovative antibody therapeutics development

• Calculate accurate success rates for commercially sponsored antibody therapeutics

The database's user-friendly interface allows both broad and specific searches, making it a versatile tool for various research needs.

How can researchers assess antibody stability for research applications?

Antibody stability assessment is crucial for research applications. Based on the search results, methodologies include:

• Library-scale thermal challenge assays: This approach subjects multiple antibody variants to thermal stress simultaneously to identify the most stable constructs. This technique was employed in the optimization of MM-141, a tetravalent bispecific antibody .

• Yeast display platforms: Researchers can use yeast display combined with structure-guided antibody design to discover stable and active single-chain variable fragments (scFvs). This approach allows for rapid screening of numerous variants .

• Serum stability testing: Assessment of antibody stability in serum conditions is critical for predicting in vivo performance. This involves incubating antibodies in serum and measuring retained activity over time .

When designing stability assessments, researchers should consider multiple parameters including thermal stability, resistance to aggregation, and maintenance of binding activity under various conditions. Integrating biophysical characterization with functional assays provides the most comprehensive assessment of antibody stability.

How can active learning approaches improve antibody-antigen binding prediction in experimental design?

Active learning approaches can significantly enhance antibody-antigen binding prediction efficiency, particularly in library-on-library settings. Recent research has developed fourteen novel active learning strategies for this purpose, with three algorithms demonstrating significant improvements over random data labeling approaches .

The most effective algorithm demonstrated:

• 35% reduction in required antigen mutant variants

• 28-step acceleration in the learning process compared to random baseline approaches

Key methodological considerations for implementing active learning in antibody research:

• Begin with a small labeled subset of antibody-antigen binding data

• Iteratively expand the labeled dataset using intelligent selection criteria

• Focus on out-of-distribution prediction scenarios (where test antibodies and antigens aren't represented in training data)

• Apply machine learning models to analyze many-to-many relationships between antibodies and antigens

This approach is particularly valuable when working with library-on-library screening approaches, where traditional active learning methods may not be applicable. By prioritizing which experimental data points to generate next, researchers can significantly reduce experimental costs and accelerate discovery timelines.

What are the known immunogenicity challenges with engineered antibodies and how can they be assessed?

Engineered antibodies, particularly those with modifications intended to enhance functionality, can unexpectedly trigger anti-drug antibody (ADA) responses. Research with PGT121-YTE demonstrates important considerations:

Binding ADA antibodies were induced in 70% (7/10) of macaques within two weeks of first or second PGT121-YTE injection, correlating with:

• Reduced pharmacokinetic profiles

• Loss of protective efficacy

• Interestingly, no correlation was observed with inhibitory ADA activity

These findings suggest that structural modifications, even those limited to the Fc region like YTE mutations, can potentially trigger immunogenicity through changes in structure/orientation that expose novel epitopes.

For assessment of immunogenicity, researchers should implement:

• Binding antibody assays: ELISA-based detection of anti-drug antibodies

• Functional inhibition assays: Measuring the ability of ADAs to inhibit the therapeutic activity (e.g., neutralization potential)

• Correlation with pharmacokinetic parameters: Examining how ADA development affects clearance profiles and efficacy

• Structural analyses: Investigating potential conformational changes that might expose immunogenic epitopes

The timing of ADA development relative to dosing and the relationship between binding versus inhibitory antibodies should be carefully characterized to understand the clinical relevance of immunogenic responses.

What methodological approaches enable rapid optimization of multispecific antibody-like molecules?

Multispecific antibody optimization requires concurrent engineering of multiple parameters including affinity, avidity, effector functions, and pharmaceutical properties. A rapid prototyping approach involves:

• Modular design: Separating the antibody into functional modules that can be optimized independently

• Yeast display of structure-focused antibody libraries: Creating diverse libraries of antibody fragments with targeted variations

• High-throughput biophysical profiling: Using micro-scale assays to rapidly assess stability and functionality

This approach was successfully applied to optimize MM-141, a tetravalent bispecific antibody targeting IGF-1R and ErbB3:

• Initial proof-of-concept molecule showed modest bioactivity and poor stability

• Yeast display and structure-guided design identified improved anti-IGF-1R and anti-ErbB3 scFvs

• Reformatting these optimized modules created diverse tetravalent bispecific antibodies

• The re-engineered molecules achieved complete blockade of growth factor-induced pro-survival signaling with improved stability and pharmaceutical properties

This rapid prototyping method enables optimization within a single campaign cycle rather than requiring multiple iterative design cycles, substantially reducing development time and resource requirements.

How can researchers design experiments to assess effector functions of therapeutic antibodies?

When designing experiments to evaluate antibody effector functions, researchers should consider multiple mechanisms including:

• Antibody-dependent cellular cytotoxicity (ADCC): Requires assays that measure NK cell-mediated killing of target cells coated with the therapeutic antibody

• Antibody-dependent cellular phagocytosis (ADCP): Involves measuring the uptake of antibody-coated targets by phagocytic cells

• Complement-dependent cytotoxicity (CDC): Assesses the ability of antibodies to activate complement and induce target cell lysis

Additionally, FcRn binding assays at both physiological and endosomal pH values (pH 7.4 and pH 6.0) should be conducted to assess recycling potential and half-life extension.

For multispecific antibodies like the tetravalent bispecific format described in the search results, experimental designs should verify the ability to simultaneously engage multiple antigens while maintaining these effector functions .

What are the key pharmacokinetic parameters to evaluate when characterizing novel antibody constructs?

Four essential pharmacokinetic parameters should be evaluated when characterizing novel antibody constructs:

These parameters provide complementary information about antibody clearance profiles and should be analyzed using non-compartmentalized analysis programs like Excel-based PK Solutions .

When studying modified antibodies (such as those with YTE mutations), these parameters should be correlated with both the development of anti-drug antibodies and the preservation of therapeutic efficacy to provide a comprehensive understanding of in vivo performance.

What are the recommended approaches for resolving inconsistent antibody binding data?

When researchers encounter inconsistent antibody binding data, a systematic troubleshooting approach is recommended:

• Cross-validate using multiple assay formats: Compare ELISA-based binding data with functional assays (e.g., neutralization assays) to identify potential discrepancies, as observed in the PGT121-YTE studies where binding antibody levels did not correlate with inhibitory activity .

• Evaluate antibody stability under experimental conditions: Inconsistent binding may result from differential stability under various assay conditions. Library-scale thermal challenge assays can help identify stability issues .

• Analyze binding kinetics: Determine if inconsistencies stem from differences in association or dissociation rates using surface plasmon resonance (SPR) or biolayer interferometry (BLI).

• Consider target heterogeneity: Variations in epitope presentation or accessibility may lead to inconsistent binding. Library-on-library approaches that explore many-to-many relationships between antibodies and antigens can help identify such patterns .

• Apply machine learning models: Active learning approaches can analyze patterns in binding data to identify factors contributing to inconsistencies and guide experimental design for resolving them .

By implementing these complementary approaches, researchers can identify the sources of inconsistency and develop more robust binding assays.

How might advances in computational methods enhance antibody engineering and characterization?

Computational methods are poised to transform antibody engineering and characterization through several advancing approaches:

• Active learning for binding prediction: Recent research demonstrates that active learning strategies can significantly improve experimental efficiency in antibody-antigen binding prediction. These approaches have reduced required antigen mutant variants by up to 35% and accelerated the learning process by 28 steps compared to random baseline approaches .

• Library-on-library prediction models: Machine learning models that analyze many-to-many relationships between antibodies and antigens can predict interactions in out-of-distribution scenarios, where test antibodies and antigens are not represented in training data .

• Structure-guided antibody design: Computational approaches that incorporate structural information can guide the design of antibody libraries with improved stability and activity profiles. This approach has been successfully applied in the rapid optimization of therapeutic antibody-like molecules .

• Immunogenicity prediction: Computational models may eventually help predict the likelihood of anti-drug antibody responses to modified antibodies by identifying structural changes that expose potentially immunogenic epitopes .

As these computational approaches continue to develop, they will increasingly enable researchers to prioritize experimental efforts, accelerate optimization processes, and reduce the resources required for antibody engineering and characterization.